| Medical and Health Sciences | Lifetime | 165 | US 91 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 532 | US 185 | 99.88 |
| Hematology | Lifetime | 5 | US 5 | 99.97 |
| Molecular Biology | Lifetime | 376 | US 237 | 99.83 |
| Oncology | Lifetime | 227 | US 125 | 99.63 |
| Medical Genetics | Lifetime | 76 | US 46 | 99.43 |
| Hematology | 2021-2025 | 15 | US 10 | 99.71 |
| Molecular Biology | 2021-2025 | 338 | US 88 | 98.43 |
| Oncology | 2021-2025 | 679 | US 298 | 89.75 |
| Medical Genetics | 2021-2025 | 242 | US 109 | 87.64 |
| Cancer Treatment and Pharmacology | Lifetime | 2 | US 2 | 99.98 |
| Peptidase Inhibition and Analysis | Lifetime | 5 | US 3 | 99.96 |
| Multiple Myeloma Research and Treatments | Lifetime | 3 | US 3 | 99.98 |
| Protein Degradation and Inhibitors | Lifetime | 3 | US 3 | 99.96 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | Lifetime | 4 | US 4 | 99.91 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 9 | US 7 | 99.83 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 32 | US 23 | 99.86 |
| Ubiquitin and proteasome pathways | Lifetime | 67 | US 39 | 99.56 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 58 | US 36 | 99.39 |
| Cancer Mechanisms and Therapy | Lifetime | 67 | US 38 | 99.06 |
| Hematological disorders and diagnostics | Lifetime | 61 | US 36 | 98.82 |
| Cancer therapeutics and mechanisms | Lifetime | 200 | US 120 | 98.81 |
| Platelet Disorders and Treatments | Lifetime | 283 | US 116 | 98.21 |
| Lymphoma Diagnosis and Treatment | Lifetime | 639 | US 294 | 98.45 |
| Peripheral Neuropathies and Disorders | Lifetime | 224 | US 77 | 98.13 |
| Angiogenesis and VEGF in Cancer | Lifetime | 486 | US 225 | 97.13 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 725 | US 319 | 96.94 |
| Economic and Financial Impacts of Cancer | Lifetime | 557 | US 354 | 94.64 |
| Chemokine receptors and signaling | Lifetime | 461 | US 181 | 94.24 |
| Pharmaceutical Economics and Policy | Lifetime | 979 | US 401 | 91.15 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 643 | US 154 | 84.73 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 18 | US 6 | 99.73 |
| Protein Degradation and Inhibitors | 2021-2025 | 15 | US 6 | 99.60 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 22 | US 11 | 98.97 |
| Peptidase Inhibition and Analysis | 2021-2025 | 72 | US 20 | 98.27 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 136 | US 71 | 98.25 |
| Cancer Mechanisms and Therapy | 2021-2025 | 44 | US 7 | 96.68 |
| Cancer Treatment and Pharmacology | 2021-2025 | 145 | US 47 | 97.22 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 333 | US 160 | 92.31 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 157 | US 73 | 84.96 |
| Ubiquitin and proteasome pathways | 2021-2025 | 837 | US 220 | 82.79 |
| Hematological disorders and diagnostics | 2021-2025 | 810 | US 196 | 52.35 |
